Ralph Berry
Psychiatry · Glens Falls, NYNPI 1972591097
Payments from drug & device makers
Across 141 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$486
- Otsuka America Pharmaceutical, Inc.$362
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$266
- Alkermes, Inc.$171
- Indivior Inc.$142
- Braeburn Inc.$133
- plus $601 from 10 others
What the payments were for
- Food & beverage$2,161100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 40 | $486 |
| Otsuka America Pharmaceutical, Inc. | 27 | $362 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $266 |
| Alkermes, Inc. | 9 | $171 |
| Indivior Inc. | 7 | $142 |
| Braeburn Inc. | 7 | $133 |
| Neurocrine Biosciences, Inc. | 6 | $106 |
| Corium, LLC | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 6 | $95 |
| Axsome Therapeutics, Inc. | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 3 | $78 |
| Lundbeck LLC | 3 | $52 |
| AbbVie | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,161 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 133 | $22,723 |
| VraylarCariprazine Hcl | 13 | $18,504 |
| Chlorpromazine Hcl | 12 | $1,799 |
| Acamprosate Calcium | 11 | $1,627 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $1,266 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 25 | $1,150 |
| Aripiprazole | 14 | $1,049 |
| Clonazepam | 65 | $718 |
| Buprenorphine Hcl | 12 | $538 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $476 |
| Duloxetine Hcl | 21 | $413 |
| Hydroxyzine Hcl | 29 | $382 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $336 |
| Ziprasidone Hcl | 15 | $331 |
| Gabapentin | 26 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $43 | $18,50413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Glens Falls
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.